Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158417 · ClinicalTrials.gov registry record · NA
Resveratrol in Type2 Diabetes and Obesity
A NA study, sponsored by University at Buffalo.
- Terminated
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT01158417 is a NA study that was terminated before completion, run by University at Buffalo. The registered enrollment target is 15 participants.
The verdict
NCT01158417, a NA study, was terminated before completion, sponsored by University at Buffalo.
- TERMINATED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo.
Interventions
- DRUG Placebo
- DRUG Resveratrol 40 mg oral three times a day
- DRUG Resveratrol 500 mg oral once daily.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-07-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158417
The ClinicalTrials.gov registry entry for NCT01158417 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01158417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158417 about?
NCT01158417 is a clinical study titled "Resveratrol in Type2 Diabetes and Obesity". The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo.
What is the current status of trial NCT01158417?
This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2008-12. Estimated completion is 2012-07-08.
What interventions are being tested in trial NCT01158417?
The interventions under investigation include: Placebo (DRUG), Resveratrol 40 mg oral three times a day (DRUG), Resveratrol 500 mg oral once daily. (DRUG).
Who is sponsoring clinical trial NCT01158417?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.